Table 4.
Genetic and patient characteristics between clusters of Klebsiella pneumoniae
| Total | Cluster group
|
P-valuea | |||
|---|---|---|---|---|---|
| KP common VF | KP common VF with ybtS | KP common VF with kfu | |||
|
| |||||
| Genetic characteristics n (%) | (n=82) | (n=40) | (n=27) | (n=15) | |
|
| |||||
| ESBL sequence | 0.9 | ||||
| CTX-M-15 | 74 (90) | 36 (90) | 24 (89) | 14 (93) | |
| CTX-M-14 | 2 (2) | 1 (3) | 1 (4) | 0 (0) | |
| TEM-15 | 4 (5) | 2 (5) | 1 (4) | 1 (7) | |
| Ciprofloxacin | |||||
| Sensitive | 8 (10) | 4 (10) | 2 (7) | 2 (13) | 0.9 |
| Trimethoprime–sulfamethoxazole | |||||
| Sensitive | 11 (13) | 7 (18) | 2 (7) | 2 (13) | 0.5 |
| Aminoglycoside phenotype | 0.004 | ||||
| Sensitive | 3 (4) | 1 (3) | 0 (0) | 2 (13) | |
| AAC(3)-II | 55 (67) | 22 (55) | 23 (85) | 10 (67) | |
| AAC(6′) | 22 (27) | 17 (43) | 3 (11) | 2 (13) | |
| APH(3′) | 2 (2) | 0 (0) | 1 (4) | 1 (7) | |
| MLST | <0.001 | ||||
| ST29 | 19 (23) | 1 (3) | 17 (63) | 1 (7) | |
| ST323 | 16 (20) | 14 (35) | 2 (7) | 0 (0) | |
| ST147 | 11 (13) | 10 (25) | 0 (0) | 1 (7) | |
| ST405 | 5 (6) | 0 (0) | 0 (0) | 5 (33) | |
| Others | 31 (38) | 15 (37) | 8 (30) | 8 (53) | |
| Relaxase (N=56) | 0.001 | ||||
| FIIK | 23 (41) | 15 (56) | 3 (16) | 5 (50) | |
| Untypable | 17 (30) | 9 (33) | 6 (32) | 2 (20) | |
| F | 8 (14) | 1 (4) | 7 (37) | 0 (0) | |
| Others | 8 (16) | 2 (7) | 3 (15) | 3 (30) | |
|
| |||||
| Patient characteristics | (n=69) | (n=32) | (n=22) | (n=15) | |
|
| |||||
| Age in yearsb | 64 (56–80) | 63 (54–84) | 70 (59–76) | 63 (58–88) | 0.9 |
| % Male | 68 | 69 | 68 | 67 | 0.9 |
| Any comorbidity | 52 (75) | 23 (72) | 18 (82) | 11 (73) | 0.8 |
| At risk exposure <3 months | 60 (87) | 27 (84) | 20 (91) | 13 (87) | 0.9 |
| Hospitalization | 48 (70) | 18 (56) | 20 (91) | 10 (67) | 0.02 |
| Trip abroad | 6 (9) | 0 (0) | 3 (14) | 3 (20) | 0.02 |
| Antibiotics | 48 (70) | 24 (75) | 14 (64) | 10 (67) | 0.7 |
| Episode | 0.4 | ||||
| Colonized | 42 (61) | 21 (66) | 13 (59) | 8 (53) | |
| Infection | 27 (39) | 11 (34) | 9 (41) | 7 (47) | |
| Acquisition | 0.17 | ||||
| Nosocomial | 56 (81) | 26 (81) | 20 (91) | 10 (67) | |
| Community-acquired | 13 (19) | 6 (19) | 2 (9) | 5 (33) | |
| Associated bacteremia | 8 (12) | 3 (9) | 5 (23) | 0 (0) | 0.11 |
| Suspected location of infection | 0.2 | ||||
| Urine | 9 (36) | 3 (33) | 1 (11) | 5 (71) | |
| Lungs | 8 (32) | 2 (22) | 4 (44) | 2 (29) | |
| Digestive tract | 5 (20) | 3 (33) | 2 (22) | 0 (0) | |
| Skin and soft tissue | 3 (12) | 1 (11) | 2 (22) | 0 (0) | |
| Length of stayb | 29 (19–63) | 30 (20–86) | 42 (17–82) | 24 (19–47) | 0.5 |
| Transferred to intensive care (N=26) | 6 (23) | 2 (18) | 2 (22) | 2 (33) | 0.8 |
| Death after 12 months (N=55) | 24 (44) | 9 (39) | 8 (44) | 7 (50) | 0.8 |
Notes: Characteristics of 82 K. pneumonia isolates from 69 patients were compared between three clusters of VFs.
a
Significance was determined using Kruskal–Wallis test for continuous variables and Pearson chi-squared test or Fisher’s exact test for categorical variables.
b
Median (IQR).
Abbreviations: ESBL, extended spectrum β-lactamase; VFs, virulence factors.